Age, median (range) years | 48 (20–84) |
No of female patients (%) | 104 (88) |
Ethnicity, N (%) | |
Caucasian | 85 (72) |
Indian/South Asian | 20 (17) |
African/Caribbean | 12 (10) |
Chinese | 1 (1) |
Positive ANA, N (%) | 118 (100) |
No of positive ANA specificities, median (range) | 1 (1–4) |
Autoantibody-positive specificities, N (%) | |
Anti-dsDNA | 42 (36) |
10–20 IU/mL | 15 (13) |
21–50 IU/mL | 18 (15) |
>50 IU/mL | 9 (8) |
Anti-Ro | 50 (42) |
<8 AI | 24 (20) |
≥8 AI | 26 (22) |
Anti-La | 9 (8) |
Anti-Smith | 5 (4) |
Anti-Chromatin | 17 (14) |
Anti-RNP | 2 (2) |
Anti-Ribosomal P | 0 (0) |
Anti-Sm/RNP | 16 (14) |
Anti-Cardiolipin/anti-B2-glycoprotein | 5 (4) |
Positive lupus anticoagulant, N (%) | 4 (3) |
Concurrent positive RF, N (%) | 11 (9) |
Low titre (<50 iU/mL), N (%) | 5 (4) |
High titre (≥50 iU/mL), N (%) | 6 (5) |
Concurrent positive anti-CCP antibody, N (%)* | 3 (3) |
Low complement levels (C3 or C4), N (%) | 8 (7) |
No of clinical criteria, N (%) | |
0 | 20 (17) |
1 | 98 (83) |
Clinical criteria present, N (%) | |
Acute or sub-acute cutaneous lupus erythematosus† | 27 (24) |
Chronic cutaneous lupus erythematosus | 1 (1) |
Oral or nasal ulcers | 4 (3) |
Non-scarring alopecia | 5 (4) |
Arthritis | 43 (36) |
Serositis | 1 (1) |
Renal | 0 (0) |
Neurological | 0 (0) |
Haemolytic anaemia | 0 (0) |
Leucopaenia or lymphopaenia | 12 (10) |
Thrombocytopenia | 5 (4) |
Glandular signs | 0 (0) |
Family history of autoimmune rheumatic disease, N (%)‡ | 43 (36) |
Ever smoked, N (%) | 45 (38) |
*All patients had low anti-CCP antibody titre (<50 U/mL).
†Only 1 patient had SCLE lesion.
‡First-degree or second-degree relative with autoimmune rheumatic disease.
AI-CTD, autoimmune-related connective tissue disease; ANA, antinuclear antibody; CCP, cyclic citrullinated peptide; dsDNA, double-stranded DNA; RF, rheumatoid factor; RNP, ribonucleic protein.